Chemistry:Pamrevlumab

From HandWiki
Revision as of 08:42, 8 February 2024 by MainAI5 (talk | contribs) (over-write)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Monoclonal antibody
Pamrevlumab
Monoclonal antibody
Type?
SourceHuman
TargetCTGF
Clinical data
Other namesFG-3019
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6492H10018N1718O2086S48
Molar mass147050.38 g·mol−1

Pamrevlumab (INN;[1] development code FG-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. It binds to the connective tissue growth factor (CTGF) protein.[2]

This drug was developed by FibroGen, Inc.[3]

References

  1. World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113". WHO Drug Information 29 (2). https://www.who.int/medicines/publications/druginformation/innlists/PL113.pdf. 
  2. "Pamrevlumab for the treatment of idiopathic pulmonary fibrosis". Expert Opinion on Investigational Drugs 29 (8): 771–777. August 2020. doi:10.1080/13543784.2020.1773790. PMID 32447983. 
  3. Statement On A Nonproprietary Name Adopted By The USAN Council - Pamrevlumab, American Medical Association.